ARCUS Enterprises

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies. The company leverages its deep expertise in the ATP-adenosine pathway and other immune-evasion mechanisms to create a robust pipeline of small molecules and antibodies. Its lead programs include domvanalimab (anti-TIGIT), zimberelimab (anti-PD-1), and quemliclustat (CD73 inhibitor), often studied in combination. Arcus has established a significant strategic partnership with Gilead Sciences to co-develop and co-commercialize its portfolio. The company's approach emphasizes rational combinations to improve clinical outcomes in various solid tumors. By targeting multiple nodes of the immune response, Arcus aims to overcome resistance to current checkpoint inhibitors.